QuidelOrtho Corporation (QDEL)
QDELNASDAQ-GSBiotechnology: In Vitro & In Vivo Diagnostic Substances
$11.52
-0.5700 (-4.71%) today
At the close, Nov 10, 4:00 PM ET. After hours $11.52 –
- Market cap
- $790.42m
- P/E
- 13.4
- EPS, last 4 quarters
- $0.8600
- Dividend yield
- –
- Day range
- $11.38 to $12.15
- 52-week range
- $9.92 to $35.58
- Average volume
- 1.98m
- Previous close
- $12.09
Analysts
2 coveringHold1 buy, 0 hold, 1 sell
Targets a year out average $12.00, +4.2% from here
Earnings
next estimate $0.4700Next report
Dec 2025
+7.0%
Mar 2026
-110.8%
Jun 2026
+425.0%
Sep 2026
+72.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $723.60m | $619.80m | $630.90m | $618.90m |
| Gross profit | $320.40m | $263.80m | $272.90m | $289.60m |
| Operating income | -$66.30m | -$31.80m | -$21.80m | -$7.50m |
| Net income | -$130.70m | -$91.80m | -$92.90m | -$53.80m |
Last four quarters: revenue $2.59bn, margin -14.2%, free cash flow -$117.10m
News
8 latest- QuidelOrtho (QDEL) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- What QuidelOrtho (QDEL) Said on Its Q3 Earnings CallMarketBeat · 7 days ago
- QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue EstimatesZacks · Nov 3, 2026
- QuidelOrtho Corporation Q3 Earnings Summary RTTNews · Nov 3, 2026
- Reasons to Add QuidelOrtho Stock to Your Portfolio for NowZacks · Oct 14, 2026
- QuidelOrtho Reaches Analyst Target PriceBNK Invest · Oct 14, 2026
- Here's What Is Shaping Abbott's Diagnostics GrowthZacks · Aug 24, 2026
- QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk ConcernsZacks · Aug 17, 2026
The company
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes - from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- quidelortho.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.